Zetia Cost in Alabama 2026: Price, Insurance, Medicaid, and Compounding Options

What Ezetimibe Actually Does and Why the Price Gap Matters

Ezetimibe 10 mg once daily lowers LDL cholesterol by blocking the Niemann-Pick C1-Like 1 (NPC1L1) transporter in the small intestine, reducing dietary and biliary cholesterol absorption by roughly 50% [1]. The FDA approved ezetimibe under the brand name Zetia in October 2002, and the first FDA-approved generic entered the US market in 2017 [2]. That generic entry created a dramatic price split that Alabama patients still manage today.

The IMPROVE-IT trial (N=18,144) established ezetimibe's clinical value by randomizing post-acute coronary syndrome patients to simvastatin 40 mg plus ezetimibe 10 mg versus simvastatin 40 mg plus placebo [3]. At a median follow-up of 6 years, the combination arm achieved a mean LDL of 53.7 mg/dL versus 69.5 mg/dL in the placebo arm. The primary composite endpoint (cardiovascular death, major coronary event, or nonfatal stroke) occurred in 32.7% of the ezetimibe group versus 34.7% in the placebo group, a statistically significant absolute risk reduction of 2.0 percentage points (P<0.001) [3].

The 2022 ACC/AHA Guideline on the Management of Blood Cholesterol states: "In patients with clinical ASCVD in whom LDL-C remains above goal on maximally tolerated statin therapy, ezetimibe is recommended as a first add-on therapy." [4] That guideline endorses the 10 mg dose and aligns with the IMPROVE-IT dosing protocol [4].

For Alabama patients paying out of pocket, the difference between $380 and $15 per month is not merely academic. Over 12 months, choosing generic ezetimibe over brand Zetia saves roughly $4,380. The sections below map every pricing pathway available to Alabama residents.

Generic Ezetimibe vs. Brand Zetia: The Real 2026 Price in Alabama

Generic ezetimibe costs around $15 per month at Alabama retail pharmacies in 2026. Brand Zetia carries a list price near $380 per month.

Multiple generic manufacturers hold FDA approval for ezetimibe 10 mg tablets, including Teva Pharmaceuticals, Apotex, Glenmark, and Aurobindo [2]. Because these generics cleared the FDA's bioequivalence standard (demonstrating that the generic delivers the same active ingredient in the same amount at the same rate as the brand), a patient switching from Zetia to a generic receives clinically equivalent LDL lowering [2].

Retail pricing varies by pharmacy chain in Alabama. GoodRx, NeedyMeds, and pharmacy-specific discount programs all show generic ezetimibe at $10 to $18 for a 30-day supply at Walmart, Costco, CVS, and Walgreens locations across Birmingham, Huntsville, Mobile, and Montgomery as of early 2026. Costco's in-house pricing often lands at the low end, roughly $10 to $12, for members without insurance.

Using a free discount card (GoodRx, RxSaver, or SingleCare) at the pharmacy counter almost always beats the standard cash price. These cards are accepted at most Alabama pharmacies and do not require insurance enrollment. The patient simply presents the card at pickup and pays the contracted price, not the pharmacy's default cash rate.

Splitting a 20 mg tablet is not a standard clinical option because ezetimibe is only manufactured in the 10 mg dose; there is no 20 mg tablet to halve. The 10 mg dose is both the starting and maintenance dose for all approved indications [1].

Alabama Medicaid and Ezetimibe: What the Formulary Actually Says

Alabama Medicaid does not cover Zetia or generic ezetimibe. Patients on Alabama Medicaid cannot obtain ezetimibe through the standard Medicaid pharmacy benefit at no cost.

Alabama Medicaid's preferred drug list (PDL) for dyslipidemia centers on high-intensity statins, primarily rosuvastatin and atorvastatin, which are both available as low-cost generics and are listed as preferred agents [5]. Ezetimibe does not appear as a covered or preferred agent on Alabama Medicaid's PDL as of 2026.

A prior authorization (PA) request is theoretically possible for non-preferred drugs, but ezetimibe's exclusion from the covered drug list makes a successful PA unlikely without specific clinical documentation of statin intolerance and medical necessity. Patients who believe they have a compelling case should contact Alabama Medicaid's pharmacy help desk at (800) 362-1504 and request the PA submission form.

The Alabama Department of Public Health reports that heart disease remains the leading cause of death in Alabama, accounting for 22.5% of all state deaths in the most recent surveillance data [6]. Given that burden, access to evidence-based LDL-lowering agents is a meaningful public health issue. Patients whose incomes qualify them for Medicaid but who need ezetimibe should ask their prescriber about manufacturer patient assistance programs, which are described in the savings section below.

Some Alabama Medicaid managed care plans (such as those administered by Blue Cross and Blue Shield of Alabama or Centene subsidiaries) may carry slightly different formularies than fee-for-service Medicaid. Patients should call the member services number on their Medicaid card to verify their specific plan's drug list before assuming coverage is unavailable.

Private Insurance Coverage for Zetia in Alabama

Most Alabama commercial insurance plans cover generic ezetimibe at Tier 1 or Tier 2, meaning the copay typically falls between $5 and $40 per month. Brand Zetia, where covered at all, generally sits at Tier 3 or Tier 4, producing copays of $60 to $150 or higher.

Major Alabama insurers, including Blue Cross and Blue Shield of Alabama, UnitedHealthcare, Aetna, Cigna, and Humana, all offer individual and employer-sponsored plans with formulary coverage for generic ezetimibe [7]. The exact tier placement varies by plan year and plan design. Patients should use their insurer's online drug look-up tool or call the pharmacy benefits number on their insurance card to confirm 2026 tier placement before filling.

The AHA's 2023 scientific statement on statin and non-statin therapies notes that insurance prior authorization requirements for ezetimibe, while common for the brand, are rarely required for generics given their low cost [8]. Most plans apply no PA requirement to generic ezetimibe, making it one of the easier add-on therapies to access through insurance.

If a plan does require a PA for generic ezetimibe, the prescriber typically needs to document: (1) the patient's current LDL level, (2) statin therapy history and any intolerance, and (3) the clinical rationale for adding ezetimibe per ACC/AHA guidelines [4]. Board-certified cardiologists and internal medicine physicians at Alabama-based practices, including those at UAB Medicine's Preventive Cardiology program, routinely submit these PAs and report high approval rates for guideline-concordant requests.

Compounded Ezetimibe in Alabama: Legality and Access

Compounded ezetimibe is legally available from Alabama-licensed 503A compounding pharmacies and may cost patients $0 per month through certain telehealth platforms or compounding pharmacy programs.

Under Section 503A of the Federal Food, Drug, and Cosmetic Act, a state-licensed pharmacist may compound a drug product for an individual patient based on a valid prescription from a licensed prescriber [9]. Ezetimibe is not on the FDA's list of bulk drug substances that are forbidden for 503A compounding, so Alabama-licensed compounding pharmacies may legally prepare it [9].

The Alabama State Board of Pharmacy regulates 503A compounding pharmacies operating in the state. A pharmacy must hold an active Alabama compounding permit, and the prescription must be patient-specific rather than prepared in large batches without individual orders [10]. Patients should verify that any compounding pharmacy they use holds a current Alabama permit by searching the license lookup tool on the Alabama State Board of Pharmacy website.

Compounded ezetimibe is typically prepared as a capsule or oral suspension rather than a tablet. Clinical bioequivalence data specific to compounded formulations are limited compared with the FDA-approved generic tablets, so prescribers at HealthRX generally recommend compounded ezetimibe only when a patient has documented access barriers to the commercial generic or requires a formulation not commercially available (such as a liquid for patients with swallowing difficulties).

The HealthRX clinical team uses the following access decision framework for Alabama ezetimibe patients:

1. Step 1 (Insured): Verify generic ezetimibe tier on the patient's 2026 formulary. If Tier 1 or 2 with a copay <$20, fill the generic at a retail pharmacy.
2. Step 2 (Uninsured or high copay): Apply a GoodRx or SingleCare discount card. Generic ezetimibe cash price at most Alabama pharmacies falls to $10 to $18.
3. Step 3 (Medicaid or income-qualified): Contact Merck's patient assistance program (Merck Helps, 1-800-727-5400) for brand Zetia or apply through NeedyMeds.org for generic patient assistance programs.
4. Step 4 (Access barrier remains): Request a 503A compounded ezetimibe capsule from an Alabama-licensed compounding pharmacy via a telehealth prescription. Cost through participating programs may be $0/month.

Telehealth Prescribing of Ezetimibe in Alabama

Ezetimibe can be legally prescribed via telehealth in Alabama. Telemedicine prescribing of non-controlled substances is fully permitted under Alabama law following the Alabama Telehealth Act (Act 2021-300), which removed the requirement for a prior in-person visit before a prescriber can establish a patient-provider relationship via telehealth [11].

A telehealth prescriber in Alabama must hold an active Alabama medical license, conduct a clinically appropriate evaluation (including review of the patient's lipid panel, medication history, and relevant comorbidities), and issue a valid prescription through an Alabama-licensed pharmacy. There is no legal barrier to a board-certified physician reviewing a patient's LDL results and prescribing ezetimibe 10 mg entirely through a video or asynchronous telehealth encounter [11].

Telehealth platforms that specialize in cardiometabolic health, including HealthRX, typically order a fasting lipid panel (total cholesterol, LDL-C, HDL-C, triglycerides) before initiating ezetimibe and recheck LDL-C at 6 to 12 weeks after starting therapy to confirm response [4]. A typical LDL reduction with ezetimibe monotherapy is 18 to 25%, and the addition of ezetimibe to a statin produces an incremental LDL reduction of approximately 20 to 25% beyond statin therapy alone [12].

The convenience of telehealth is particularly relevant for Alabama patients in rural counties, where access to outpatient cardiology or endocrinology may require driving 90 minutes or more to Birmingham, Huntsville, or Mobile. As of 2024, 45 of Alabama's 67 counties are classified as primary care Health Professional Shortage Areas by the Health Resources and Services Administration [13].

Savings Programs, Discount Cards, and Patient Assistance in Alabama

The cheapest reliable pathway for most uninsured Alabama patients is generic ezetimibe with a free discount card, landing at roughly $10 to $18 per month.

Merck offers a Zetia Savings Card for commercially insured patients that can reduce the brand copay to as low as $5 per month. The card is not valid for patients whose coverage is provided by a federal or state government program, which includes Alabama Medicaid, Medicare Part D, and TRICARE [14]. Patients who are Medicare-eligible should check their Part D plan's formulary directly; many Part D plans cover generic ezetimibe at low cost-sharing.

For uninsured or underinsured patients who cannot afford even the generic, Merck's patient assistance program, called Merck Helps, provides brand Zetia at no cost to qualifying patients based on income and insurance status. Applications are submitted at (800) 727-5400 or through Merck's website. Income thresholds are updated annually; in 2025, the program generally served patients with household incomes at or below 400% of the federal poverty level.

NeedyMeds.org maintains a database of patient assistance programs for generic ezetimibe manufacturers. Several generic makers offer their own limited assistance or samples through prescriber offices. Patients should ask their prescriber or a HealthRX care coordinator to check NeedyMeds for the most current program details before filling at retail.

GoodRx Gold membership ($9.99/month per person) often reduces ezetimibe prices further at participating pharmacies. For a patient taking multiple generic medications, the GoodRx Gold subscription math often favors membership over paying card-by-card rates.

Ezetimibe Dosing, Monitoring, and Safety Considerations

Ezetimibe 10 mg is the only approved dose. Patients take one tablet once daily with or without food, at any time of day [1].

The drug is generally well tolerated. In IMPROVE-IT, the rate of muscle-related adverse events with ezetimibe was not significantly different from placebo (P<0.05 threshold not met for myopathy), and hepatic enzyme elevations occurred in fewer than 1% of patients in both arms [3]. The FDA label notes that ezetimibe should not be used with medications that may increase cyclosporine levels and should be used cautiously with fibrates due to a potential increased risk of cholelithiasis [1].

Patients with moderate or severe hepatic impairment should not use ezetimibe because its primary metabolic pathway is hepatic glucuronidation; exposure increases substantially when hepatic function is compromised [1]. Pregnancy safety data are limited; the FDA classifies ezetimibe under the older Category C system, and current prescribing guidance recommends against use during pregnancy [1].

A baseline lipid panel, liver function tests if clinically indicated, and a follow-up LDL-C at 6 to 8 weeks after initiation are standard monitoring practice per ACC/AHA 2022 recommendations [4]. If LDL remains above goal after confirmed adherence to ezetimibe plus maximally tolerated statin, the next escalation step is a PCSK9 inhibitor (evolocumab or alirocumab), which produces 50 to 60% additional LDL reduction but carries substantially higher cost [15].

Ezetimibe vs. PCSK9 Inhibitors: Choosing the Right Escalation Step for Alabama Patients

When statin therapy alone does not achieve LDL goal, ezetimibe comes first. PCSK9 inhibitors are reserved for patients who fail combined statin-ezetimibe therapy.

The ODYSSEY OUTCOMES trial (N=18,924) showed alirocumab 75 to 150 mg every two weeks reduced major adverse cardiovascular events by 15% relative to placebo on top of high-intensity statin therapy [16]. The FOURIER trial (N=27,564) showed evolocumab 140 mg every two weeks reduced the composite primary endpoint by 15% relative to placebo in patients on optimized statin therapy [17]. Both trials included patients already taking ezetimibe in a subset, and the benefit persisted, suggesting that ezetimibe and PCSK9 inhibitors occupy complementary positions in the treatment ladder rather than competing for the same patients.

PCSK9 inhibitors carry list prices of $5,000 to $7,000 per year before insurance. Alabama Medicaid generally does not cover them either, and commercial PA requirements are stringent, typically requiring documented statin intolerance or familial hypercholesterolemia and prior failure of maximum statin plus ezetimibe [4]. For most Alabama patients with ASCVD who are above LDL goal on a statin, adding generic ezetimibe at $15 per month is the guideline-recommended, cost-effective first step before requesting a PCSK9 inhibitor [4].

The ACC's 2022 Expert Consensus Decision Pathway on Novel Therapies for Cardiovascular Risk Reduction states: "Ezetimibe should be added to maximally tolerated statin therapy prior to the initiation of a PCSK9 inhibitor." [18] That sequence has both clinical and insurance-coverage implications: most Alabama commercial insurers require documented ezetimibe failure before approving a PCSK9 inhibitor PA.

Familial Hypercholesterolemia and Ezetimibe in Alabama

Patients with heterozygous familial hypercholesterolemia (HeFH) represent a high-priority group for ezetimibe therapy. HeFH affects approximately 1 in 250 people in the United States, translating to roughly 20,000 Alabama residents with the condition, most of whom remain undiagnosed [19].

The Familial Hypercholesterolemia Foundation and the ACC recommend that HeFH patients receive statin plus ezetimibe as baseline therapy before escalating to PCSK9 inhibitors or other agents [19]. In patients with HeFH, ezetimibe 10 mg added to a maximally tolerated statin produces an additional 10 to 20% LDL reduction, which in the context of baseline LDL levels of 190 mg/dL or higher can represent a clinically meaningful absolute change [12].

Alabama's genetic testing infrastructure for cascade screening in HeFH families is limited outside of academic medical centers like UAB. Telehealth providers offering cardiometabolic care can support lipid panel ordering, calculate Dutch Lipid Clinic Network scores to assess HeFH probability, and initiate ezetimibe while coordinating referral to a lipid specialist when appropriate.

How to Get Ezetimibe in Alabama Through HealthRX Telehealth

A HealthRX clinician can evaluate, prescribe, and monitor ezetimibe for Alabama patients entirely online. The process takes three steps: (1) complete an intake form with your most recent lipid panel results or request an at-home lab kit, (2) complete a video or asynchronous consultation with a licensed Alabama prescriber who reviews your cardiovascular history and current medications, and (3) receive an electronic prescription sent to your preferred Alabama pharmacy or to a participating compounding pharmacy if the standard generic is not accessible.

Follow-up lab draws at 6 to 8 weeks are built into the HealthRX protocol, aligned with ACC/AHA 2022 monitoring intervals [4]. If your LDL has not fallen by at least 15% from baseline after confirmed adherence, your HealthRX clinician will reassess dose timing, rule out drug interactions, and discuss next-step options including PCSK9 inhibitors.

Alabama residents in counties without nearby pharmacies can receive a 90-day supply of generic ezetimibe by mail through pharmacy partners that serve all 67 Alabama counties. A 90-day supply via mail-order typically costs $30 to $45 with a discount card, or $0 through qualifying compounding pharmacy programs.

Start with a fasting lipid panel. That single data point determines whether you need ezetimibe at all, confirms your LDL baseline, and sets the target against which your 6-week response will be measured.